Marc  Benioff net worth and biography

Marc Benioff Biography and Net Worth

Marc Russell Benioff (born September 25, 1964) is the founder, chairman and CEO of salesforce.com, a cloud computing company.

Benioff started salesforce.com in March 1999 in a rented San Francisco apartment and defined its mission as The End of Software®. He is “credited with turning the software industry on its head” by using the Internet to “revamp the way software programs are designed and distributed.” He has long evangelized software as a service as the model that would replace traditional enterprise software. He is the creator of the term “platform as a service” and has extended salesforce.com’s reach by allowing customers to build their own applications on the company’s architecture, or in the salesforce.com “cloud.” He is the author of three books, including the national best seller Behind the Cloud. He currently serves on the board of Cisco.

Early life and education:
Benioff was raised in a Jewish family in the San Francisco metropolitan area. He graduated from Burlingame High School in 1982. Benioff received a Bachelor of Science in Business Administration from the University of Southern California Epyx published his King Arthur's Heir, The Nightmare, Escape from Vulcan's Isle, and Crypt of the Undead. He worked as an assembly language programmer at the Macintosh Division of Apple Computer, where he was inspired by the company and its co-founder, Steve Jobs. Prior to founding salesforce.com, Benioff was at Oracle Corporation for 13 years in a variety of executive positions in sales, marketing, and product development. At 23, he was named Oracle's Rookie of the Year and three years later he was promoted to vice president, the company's youngest person to hold that title.

Influence and honors:
In 2010 Fortune named him one of the Smartest 50 People in Tech as well as one of the Top 50 People in Business. The San Francisco Business Times named Benioff 2009 Executive of the Year, "for defying the fierce economic downdraft--and taking the lead role in the creation of an industry."

What is Marc Benioff's net worth?

The estimated net worth of Marc Benioff is at least $20.07 million as of December 18th, 2024. Mr. Benioff owns 12,162,457 shares of Acumen Pharmaceuticals stock worth more than $20,068,054 as of January 21st. This net worth approximation does not reflect any other assets that Mr. Benioff may own. Learn More about Marc Benioff's net worth.

How do I contact Marc Benioff?

The corporate mailing address for Mr. Benioff and other Acumen Pharmaceuticals executives is , , . Acumen Pharmaceuticals can also be reached via phone at 434-297-1000 and via email at investors@acumenpharm.com. Learn More on Marc Benioff's contact information.

Has Marc Benioff been buying or selling shares of Acumen Pharmaceuticals?

Marc Benioff has not been actively trading shares of Acumen Pharmaceuticals over the course of the past ninety days. Learn More on Marc Benioff's trading history.

Who are Acumen Pharmaceuticals' active insiders?

Acumen Pharmaceuticals' insider roster includes Marc Benioff (CEO), Nathan Fountain (Director), Paul Manning (Director), and John Stalfort, III (Director). Learn More on Acumen Pharmaceuticals' active insiders.

Are insiders buying or selling shares of Acumen Pharmaceuticals?

During the last year, insiders at the sold shares 4 times. They sold a total of 79,508 shares worth more than $146,556.03. The most recent insider tranaction occured on January, 3rd when CEO Daniel Joseph Oconnell sold 47,778 shares worth more than $87,911.52. Insiders at Acumen Pharmaceuticals own 7.1% of the company. Learn More about insider trades at Acumen Pharmaceuticals.

Information on this page was last updated on 1/3/2025.

Marc Benioff Insider Trading History at Acumen Pharmaceuticals

See Full Table

Marc Benioff Buying and Selling Activity at Acumen Pharmaceuticals

This chart shows Marc Benioff's buying and selling at Acumen Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1$0Total Insider BuyingTotal Insider Selling

Acumen Pharmaceuticals Company Overview

Acumen Pharmaceuticals logo
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers. The company has a license agreement with Lonza Sales AG to manufacture and commercialize sabirnetug; and a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of sabirnetug. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.
Read More

Today's Range

Now: $1.65
Low: $1.53
High: $1.70

50 Day Range

MA: $2.02
Low: $1.56
High: $2.67

2 Week Range

Now: $1.65
Low: $1.53
High: $5.09

Volume

547,063 shs

Average Volume

326,821 shs

Market Capitalization

$99.13 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.02